News

Latest news
February 22, 2024

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology

February 21, 2024

FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ --...

February 20, 2024

Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman Transition will occur on July 1, 2024 NORTH CHICAGO, Ill., Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...

More »

AbbVie on Twitter

Looking for more news from AbbVie? Follow us on social media.

News

Advanced Search
Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Societal impact

Our commitment to science is a commitment to better our society. Read our 2022 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2022 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?